Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland.

摘要: Objective: To explore the association between antiretroviral therapy in pregnancy and premature delivery, birthweight, stillbirth neonatal mortality, pregnancies HIV-infected women delivering 1990 2005.Design: Pregnancies with diagnosed HIV infection UK Ireland are notified to National Study of Pregnancy Childhood (NSHPC) through a well-established surveillance scheme.Results: The prematurity rate (< 37 weeks gestation) was higher on highly active (HAART) (14.1%, 476/3384) than mono/ dual (10.1%, 107/1061), even after adjusting for ethnicity, maternal age, clinical status injecting drug use as source acquisition [adjusted odds ratio (AOR) = 1.51, 95% confidence interval (CI), 1.19-1.93; P 0.001]. Delivery at < 35 more strongly associated HAART (AOR=2.34; CI, 1.64-3.37; 0.001). effect same whether or not included protease inhibitor. In comparison exposure mono/dual therapy, lower birthweight standardized gestational age (P 0.001), an increased risk (AOR 2.27; 0.96-5.41; 0.063).Conclusions: These findings, based comprehensive population surveillance, demonstrate HAART, possible other perinatal outcomes, including birthweight. Although beneficial effects mother-to-child transmission indisputable, monitoring remains priority. (C) 2007 Lippincott Williams & Wilkins.